Suven Life Sciences Q1 net up 16.68 pc at Rs 34.74 cr

Suven Life Sciences today reported a 16.68 per cent increase in its net profit at Rs 34.74 crore for the first quarter ended June 30, 2014.

The company had posted a net profit of Rs 29.77 crore in the corresponding quarter last fiscal, Suven Life Sciences said in a filing to BSE.

Net sales during the period under review stood at Rs 141.53 crore as against Rs 108.67 crore, up 30.23 per cent.

During the quarter, revenue from contract research and manufacturing services (CRAMS) stood at Rs 138.95 crore as compared to Rs 106.89 crore in the year-ago period.

On the other hand, income from drug discovery, development and support services stood at Rs 2.58 crore as against Rs 1.78 crore in Q1 last fiscal, the company said.

Suven's major thrust on innovative R&D in drug discovery continues with a spending of Rs 8.9 crore, which is 6.28 per cent of revenue for the quarter ended June 30, 2014, it added.

Shares of Suven Life Sciences were trading at Rs 123.15 per scrip in the morning trade, down 0.28 per cent from the previous close on BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The survey paints an optimistic future, but sees little scope for a bang

    The Economic Survey, which comes out a day before the Union budget, is widely regarded as its forerunner, an indicator of things to come 24 hours late

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schoettli

The hidden attractions of Japan

We live in the Asian century. During the past two ...

Zehra Naqvi

Star power

Being a part of the generation that gorged on Shah ...

Bubbles Sabharwal

The waking moment decides the day

There was a little girl/ Who had a little curl/ ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture